A5021313237- Breast Cancer Treatment Studies
- Patient-Provider Communication in Healthcare
- Advanced Breast Cancer Therapies
- Palliative Care and End-of-Life Issues
- Global Cancer Incidence and Screening
- HER2/EGFR in Cancer Research
- Cancer Treatment and Pharmacology
- BRCA gene mutations in cancer
- Estrogen and related hormone effects
- Patient Dignity and Privacy
- Cancer survivorship and care
- Radiomics and Machine Learning in Medical Imaging
- Cancer-related cognitive impairment studies
- Health Systems, Economic Evaluations, Quality of Life
- Cancer Immunotherapy and Biomarkers
- MRI in cancer diagnosis
- Pancreatic and Hepatic Oncology Research
- Childhood Cancer Survivors' Quality of Life
- Chronic Lymphocytic Leukemia Research
- Cancer Risks and Factors
- Breast Implant and Reconstruction
- Peptidase Inhibition and Analysis
- Medical Imaging Techniques and Applications
- Cancer-related Molecular Pathways
- Clinical practice guidelines implementation
University of Newcastle Australia
2016-2025
Breast Cancer Trials
2014-2024
Cancer Trials Australia
2022-2024
Calvary Mater Newcastle Hospital
2012-2022
Australasia Paediatric Endocrine Group
2022
Hunan Cancer Hospital
2022
Xiangya Hospital Central South University
2022
Central South University
2022
Lake Macquarie Private Hospital
2020-2021
The University of Sydney
2015-2019
BMI affects breast cancer risk and prognosis. In contrast to cytotoxic chemotherapy, CDK4/6 inhibitors are given at a fixed dose, irrespective of or weight. This preplanned analysis the global randomized PALLAS trial investigates impact on side-effect profile, treatment adherence, efficacy palbociclib.
PURPOSE The PALLAS study investigated whether the addition of palbociclib, an oral CDK4/6 inhibitor, to adjuvant endocrine therapy (ET) improves invasive disease-free survival (iDFS) in early hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2–) breast cancer. In this analysis, we evaluated palbociclib exposure and discontinuation PALLAS. METHODS Patients with stage II-III HR+, HER2– disease were randomly assigned 2 years ET versus alone. primary...
Appropriately timed cessation of chemotherapy is an important aspect good quality palliative care. There wide variation in the reported rates administration within last 30 days life.To identify predictors death receiving chemotherapy, and to propose a standard definition by which oncologists cancer centres can be compared.Patients who received at regional centre its rural outreach unit between 2009 2011 were included. An adjusted logistic regression model, including all variables, was fit...
Introduction Neoadjuvant systemic anticancer therapy (neoSACT) is increasingly used in the treatment of early breast cancer. Response to prognostic and allows locoregional adjuvant treatments be tailored minimise morbidity optimise oncological outcomes quality life. Accurate information about following neoSACT vital allow translation downstaging benefits into practice facilitate meaningful interpretation outcomes, particularly recurrence. Reporting studies, however, currently poor. The...
Concomitant intake of proton pump inhibitors (PPIs) may create drug-drug interactions, potentially impacting efficacy anticancer agents. In the phase III PALLAS trial, addition palbociclib capsules to standard adjuvant endocrine therapy in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative early breast cancer did not improve invasive disease-free survival (iDFS). We explored whether concomitant use PPIs affected outcomes treated PALLAS.
The PALLAS trial investigated the addition of palbociclib to standard adjuvant endocrine therapy reduce breast cancer recurrence. This pre-specified analysis was conducted determine whether benefited patients diagnosed with lower risk stage IIA disease compared those higher disease. an international, multicenter, randomized, open-label, phase III trial, representing a public–private partnership between Pfizer, Austrian Breast Cancer Study Group, and U.S. ALLIANCE Foundation. Patients II–III,...
PREDICT-5FU aimed to document 5-fluorouracil (5FU) exposure in a cancer population and evaluate the feasibility of 5FU capecitabine therapeutic drug monitoring (TDM) patients receiving standard doses schedules. Multicentre, prospective, observational single-arm study. Eligible adult received (infusional ≥24 h) or capecitabine. Patients were treated for gastrointestinal, breast head-and-neck cancers at four Australian hospitals. TDM was performed consecutive cycles until target area under...
Background: Helping people achieve their preferred location of care is an important indicator quality end-of-life (EOL) care. Using a sample Australian medical oncology outpatients, this study examined (1) EOL care; (2) perceived benefits and worries receiving in that location; (3) the percentage who had discussed preferences with doctor and/or support person; (4) whether they wanted to ask them where die. Methods: Adults confirmed diagnosis cancer were approached between September 2015...
An increased risk of breast cancer is associated with high serum concentrations oestradiol and testosterone in postmenopausal women, but little known about how these hormones affect response to endocrine therapy for prevention or treatment. We aimed assess the effects on efficacy aromatase inhibitor anastrozole women at risk.
Abstract Background: A previous clinical study suggested that a priming dose of programmed cell death ligand 1 (PD-L1) inhibitor monotherapy 2 weeks prior to addition chemotherapy could be more efficacious than starting all agents concurrently. Furthermore, the checkpoint therapy may allow shorter duration in selected patients. The aim this was investigate strategies lead-in Nivolumab (N) and concurrent N with 12 carboplatin paclitaxel TNBC. Methods: In multicenter Phase II study, eligible...
Abstract Background. The phase 3 PALLAS trial (NCT02513394) compared two years of the CDK4/6 inhibitor palbociclib with endocrine therapy provider choice, versus alone, as adjuvant treatment for patients Stage II-III hormone receptor-positive HER2-negative (HR+/HER2-) breast cancer. Genomic subtype (PAM50 intrinsic subtype) measured from whole-transcriptome RNA sequencing data was defined in protocol primary biomarker analysis prediction and prognosis. Clinical have been previously presented...
602 Background: We examined the efficacy and safety of neoadjuvant ipilimumab nivolumab combined with paclitaxel following suboptimal response to anthracycline-based chemotherapy in patients early-stage TNBC. Methods: This single arm multicentre phase 2 study enrolled 34 8 sites. Patients were aged ≥18 years previously untreated stage 3 TNBC required have ≥15mm tumor remaining or 10mm one positive lymph node after 4 cycles therapy. A subset at baseline was defined as < 50% reduction...
608 Background: We examined the efficacy and safety of neoadjuvant ipilimumab nivolumab combined with paclitaxel following suboptimal response to anthracycline-based chemotherapy in patients early-stage TNBC. Methods: This single arm phase 2 study enrolled 34 at 8 sites. Patients had stage 3 TNBC, after 4 cycles therapy, ≥15mm tumor remaining or ≥10mm ≥1 positive lymph node. A baseline was defined as <50% reduction volume therapy. received 1mg/kg IV 6 weekly for doses 240mg every weeks...